New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28890247.
- Also identified by DOI 10.1016/j.eururo.2017.08.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adjuvant treatment of renal cell carcinoma with vascular endothelial growth factor inhibitors is feasible and effective with careful patient selection and standard dosing levels.
Medical subject headings
- Angiogenesis Inhibitors
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Neovascularization, Pathologic
- Vascular Endothelial Growth Factor A